Early release article from Annals of Internal Medicine

January 20, 2006

PHILADELPHIA - (Jan. 20, 2006) Three case reports of liver problems after taking the antibiotic telithromycin (Ketek®) are reported in Annals of Internal Medicine today.

Researchers at Carolinas Medical Center in Charlotte, N. C., say that one of the patients died; one required and received a liver transplant; and the third recovered from drug-induced hepatitis after the antibiotic was stopped.

The article, "Severe Hepatotoxicity of Telithromycin: Three Case Reports and Literature Review" will be published in the March 21, 2006, print edition of the journal. It was released early today online and is available to the public on Jan. 20, 2006, at http://www.acponline.org/journals/annals/hepatotoxicity.htm.

"These cases could represent an unusual clustering of a rare, idiosyncratic drug reaction at one medical center," said John S. Hanson, MD, an author and hepatologist with the liver transplant center at Carolinas Medical Center.

"However, the severity of liver injury in two of our patients warrants this report in the medical literature and will alert other physicians to this possible link with telithromycin."

Dr. Hanson said that, despite the three reports, "At this point, there is not enough data to indicate major changes in prescribing habits."

All cases have been referred to the FDA's Adverse Event Reporting System.

Patients taking Ketek® should report symptoms such as malaise, weakness, or jaundice to their prescribing physicians.

Telithromycin was approved by the U.S. Food and Drug Administration in 2004 to treat acute bacterial infections from chronic bronchitis, acute bacterial sinusitis and community-acquired pneumonia.

Telithromycin, an antibiotic derived from the macrolide class of antibacterial agents, appears effective against some pneumonia strains resistant to other older antibacterials such as penicillin.

In the three cases described in the Annals of Internal Medicine article, liver problems were observed after the patients began taking telithromycin. The reports do not prove that the antibiotic caused the liver impairment. But, in the article, the authors advise "caution in prescribing this drug pending further postmarketing surveillance data."

Patients in two of the three cases reported some use of alcohol, although no prior liver damage had been noted. Authors say that the relationship between telithromycin and alcohol use "warrants further study."

Carolinas Medical Center, an academic medical center teaching hospital, is a 861-bed facility of Carolinas HealthCare System. CHS is the largest healthcare system in the Carolinas and the third largest public system in the nation.
To interview authors at Carolinas Medical Center please contact Scott White (director of media relations, 704-355-3141, scott.white@carolinashealthcare.org) or Ray Jones (director of public relations, 704-355-3141, raymond.jones@carolianshealthcare.org).

To interview Harold Sox, MD, Editor of Annals of Internal Medicine, call Susan Anderson, 215-351-2653 or 800-523-1546, ext. 2653; sanderson@acponline.org

To reach the FDA for comment on the article, call Susan Bro (301-827-3259 or 240-494-6235) or Julie Zawizsa (301-827-5674).

American College of Physicians

Related Antibiotic Articles from Brightsurf:

Pollution linked to antibiotic resistance
Antibiotic resistance is an increasing health problem, but new research suggests it is not only caused by the overuse of antibiotics.

Antibiotic resistance and the need for personalized treatments
Scientists have discovered that the microbiota of each individual determines the maintenance of antibiotic resistant bacteria in the gut: whereas in some individuals resistant bacteria are quickly eliminated, in others they are not.

Artificial intelligence yields new antibiotic
Using a machine-learning algorithm, MIT researchers have identified a powerful new antibiotic compound.

From cancer medication to antibiotic
Antibiotic-resistant bacteria are increasingly the source of deadly infections. A team of scientists from the Technical University of Munich (TUM) and the Helmholtz Center for Infection Research (HZI) in Braunschweig have now modified an approved cancer drug to develop an active agent against multidrug-resistant pathogens.

Up to two-fifths of antibiotic prescriptions in the US could be inappropriate
As much as two fifths (43%) of antibiotic prescriptions in the United States could be inappropriate, warn researchers in a study published by The BMJ today.

New understanding of antibiotic synthesis
Researchers at McGill University's Faculty of Medicine have made important strides in understanding the functioning of enzymes that play an integral role in the production of antibiotics and other therapeutics.

Cause of antibiotic resistance identified
Bacteria can change form in human body, hiding the cell wall inside themselves to avoid detection.

Cannabidiol is a powerful new antibiotic
New research has found that Cannnabidiol is active against Gram-positive bacteria, including those responsible for many serious infections (such as Staphyloccocus aureus and Streptococcus pneumoniae), with potency similar to that of established antibiotics such as vancomycin or daptomycin.

New approaches cut inappropriate antibiotic use by over 30%
A UC Davis study of nine emergency departments and urgent care centers in California and Colorado found educating physicians and patients about safe antibiotic use can cut overuse by one-third.

How certain antibiotic combinations could defeat 'superbugs'
In hospitalized patients with bacterial infections, heteroresistance is more widespread than previously appreciated.

Read More: Antibiotic News and Antibiotic Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.